Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 106Lung Neoplasms 41Neoplasms 13Neoplasm Metastasis 11Colorectal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Carcinoma 6Mesothelioma, Malignant 5Mesothelioma 5Ovarian Neoplasms 4Meningeal Carcinomatosis 4Melanoma 4Colonic Neoplasms 4Advanced Solid Tumors 4Rectal Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Bronchogenic 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thoracic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Non-squamous Non-small Cell Lung Cancer 2Non-Small Cell Lung Cancer Metastatic 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

Specimen Handling 5Magnetic Resonance Spectroscopy 5Cisplatin 4trastuzumab deruxtecan 3Platinum 3Docetaxel 3Carboplatin 3Biopsy 3pembrolizumab 2entrectinib 2darolutamide 2Trastuzumab 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Goserelin 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1sacituzumab govitecan 1pyrotinib 1pertuzumab 1luprolide acetate gel depot 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1camrelizumab 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Pemetrexed × 90 days × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡